Re: Jarow JP et al.: Clinical Trial Design For the Development of New Therapies for Non–muscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop (Urology 2014;83:262-265)-Reference-Cited by-同舟云学术

Re: Jarow JP et al.: Clinical Trial Design For the Development of New Therapies for Non–muscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop (Urology 2014;83:262-265)

Published:2014-08 Issue:2 Volume:84 Page:494-495
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Amrhein John,Kamat Ashish M.,Morales Alvaro^ORCID

Publisher

Elsevier BV

Subject

Urology

Reference5 articles.

1. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group;Steinberg;J Urol,2000

2. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure;Sternberg;J Urol,2013

3. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin;Skinner;J Urol,2013

4. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ;Rosevear;J Urol,2011

5. FDA/AUA Bladder Cancer Workshop. Clinical trial design issues: development of new therapies for non-muscle invasive bladder cancer 2013 Available at: http://www.aua2013.org/webcasts/fda-bladder-cancer-workshop.cfm. Accessed October 7, 2013.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group;Journal of Clinical Oncology;2016-06-01